Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $2.4B | $2.3B | $2.2B | $1.8B | $1.6B | $1.4B | $988M | $968M | $854M | $452M | $191M | $37M | $25M | $31M | $47M | $290M | $185M | $152M | $118M | $113M | $99M |
| Beneficio bruto | $2.4B | $2.2B | $2.1B | $1.8B | $1.6B | $1.4B | $951M | $935M | $827M | $437M | $185M | $33M | $23M | $30M | $47M | $290M | $185M | $152M | $118M | $113M | $98M |
| % de margen bruto | 96.4% | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | 96.3% | 96.6% | 96.9% | 96.7% | 96.6% | 89.5% | 91.9% | 96.4% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | 99.2% |
| Ingresos operativos (EBIT) | $971M | $872M | $605M | $171M | $201M | $287M | $110M | $369M | $439M | $166M | ($28M) | ($121M) | ($224M) | ($201M) | ($122M) | $90M | ($91M) | ($122M) | ($179M) | ($157M) | ($127M) |
| % de margen operativo | 39.8% | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | 11.1% | 38.2% | 51.4% | 36.7% | -14.7% | -326.7% | -893.9% | -640.5% | -258.0% | 30.9% | -49.4% | -80.3% | -152.1% | -138.4% | -128.5% |
| Ingresos netos | $861M | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | ($70M) | ($170M) | ($269M) | ($245M) | ($148M) | $76M | ($92M) | ($135M) | ($163M) | ($86M) | ($101M) |
| % de margen neto | 35.3% | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | -36.7% | -456.6% | -1069.4% | -781.0% | -311.2% | 26.1% | -49.9% | -89.1% | -138.2% | -76.1% | -102.9% |
| EBITDA | — | $922M | $719M | $283M | $222M | $300M | $119M | $378M | $452M | $167M | ($22M) | ($120M) | ($213M) | ($196M) | ($115M) | $100M | ($73M) | ($116M) | ($156M) | ($157M) | ($110M) |
| Beneficio por acción (EPS) | $3.17 | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | $-0.28 | $-0.81 | $-1.38 | $-1.33 | $-0.92 | $0.58 | $-0.85 | $-1.26 | $-1.54 | $-0.87 | $-1.17 |
| Acciones en circulación (M) | — | 282M | 296M | 321M | 325M | 322M | 318M | 315M | 313M | 312M | 251M | 209M | 194M | 184M | 160M | 130M | 109M | 107M | 105M | 99M | 87M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de EXEL. /companies/us/EXEL
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms